Skip to main content
Clinical Trials/NCT03680326
NCT03680326CompletedNot Applicable

Influence of Intravitreal Anti-vascular Endothelial Growth Factor Administration on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration

Hospital Hietzing0 sites43 target enrollmentStarted: February 2, 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
43
Primary Endpoint
visual acuity

Study Overview

Brief Summary

Purpose:

To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on vitreomacular interface- and retinal morphology in eyes with neovascular age-related macular degeneration (AMD) and to identify morphological markers potentially influencing disease prognosis.

Methods:

43 patients (51 eyes) with treatment naïve neovascular AMD subsequently treated with Bevacizumab 1.25mg (in 0.05ml of solution) were monitored until month 12 of follow-up. Following a loading dose of 3 monthly intravitreal anti-VEGF injections, patients were treated as-needed [pro re nata (PRN)]. Functional and morphological changes were assessed using Spectral Domain Optical Coherence Tomography (SD-OCT).

Detailed Description

This retrospective study included 43 treatment-naive patients (51 eyes) with neovascular AMD over the course of 12 months. Patients were treated with a loading dose of 3 initial monthly anti-VEGF injections (Bevacizumab 1.25mg in 0.05ml of solution-Avastin®) and were followed monthly until year 1. Re-treatment was performed if needed (pro re nata-PRN) as previously reported.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Retrospective

Eligibility Criteria

Ages
66 Years to 98 Years (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • diagnosis of treatment-naive neovascular AMD

Exclusion Criteria

  • any treatment with other anti-VEGF agents than Bevacizumab in the follow-up period
  • any other diseases leading to macular edema
  • prior vitrectomy
  • retinal or corneal laser surgery
  • high myopia (>6dpt)
  • preceding eye trauma

Outcomes

Primary Outcomes

visual acuity

Time Frame: 12 months

visual acuity testing was performed

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Hospital Hietzing
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Clara Wernigg

Dr.

Hospital Hietzing

Similar Trials